{"name":"Technische Universität Dresden","slug":"technische-universit-t-dresden","ticker":"","exchange":"","domain":"","description":"","hq":"Dresden","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"neuroscience","drugs":[{"name":"randomization between two established Chemotherapies","genericName":"randomization between two established Chemotherapies","slug":"randomization-between-two-established-chemotherapies","indication":"Other","status":"marketed"},{"name":"Ciclosporine A","genericName":"Ciclosporine A","slug":"ciclosporine-a","indication":"Other","status":"marketed"},{"name":"Cytarabine Dosage","genericName":"Cytarabine Dosage","slug":"cytarabine-dosage","indication":"Other","status":"marketed"},{"name":"Dermatop","genericName":"Dermatop","slug":"dermatop","indication":"Other","status":"phase_1"},{"name":"Placebo lead in","genericName":"Placebo lead in","slug":"placebo-lead-in","indication":"Other","status":"phase_3"},{"name":"all-trans retinoid acid","genericName":"all-trans retinoid acid","slug":"all-trans-retinoid-acid","indication":"Other","status":"marketed"},{"name":"amine fluoride/stannous fluoride","genericName":"amine fluoride/stannous fluoride","slug":"amine-fluoride-stannous-fluoride","indication":"Prevention of dental caries (cavities)","status":"marketed"},{"name":"hydrocortisonacetat 1% cream","genericName":"hydrocortisonacetat 1% cream","slug":"hydrocortisonacetat-1-cream","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"5-Azacytidin","genericName":"5-Azacytidin","slug":"5-azacytidin","indication":"Myelodysplastic syndromes","status":"phase_3"},{"name":"Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone","genericName":"Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone","slug":"cytarabine-vs-cytarabine-amsacrine-mitoxantrone","indication":"Acute myeloid leukemia (AML), particularly in relapsed or refractory disease","status":"marketed"},{"name":"Fludarabine (Flud)","genericName":"Fludarabine (Flud)","slug":"fludarabine-flud","indication":"Chronic lymphocytic leukemia (CLL)","status":"marketed"},{"name":"Gilteritinib (GILT)","genericName":"Gilteritinib (GILT)","slug":"gilteritinib-gilt","indication":"Acute myeloid leukemia (AML) with FLT3 mutation, relapsed or refractory","status":"marketed"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Elidel-Creme","genericName":"Elidel-Creme","slug":"elidel-creme","indication":"Atopic dermatitis (eczema) in adults and children ≥2 years","status":"marketed"},{"name":"Adapalen","genericName":"Adapalen","slug":"adapalen","indication":"Acne vulgaris","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Therapeutic platelet transfusion","genericName":"Therapeutic platelet transfusion","slug":"therapeutic-platelet-transfusion","indication":"Thrombocytopenia","status":"phase_3"},{"name":"Prophylactic platelet transfusion","genericName":"Prophylactic platelet transfusion","slug":"prophylactic-platelet-transfusion","indication":"Prevention of bleeding in patients with thrombocytopenia","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Piritramid (analgetic)","genericName":"Piritramid (analgetic)","slug":"piritramid-analgetic","indication":"Moderate to severe acute pain","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Midazolam (sedative)","genericName":"Midazolam (sedative)","slug":"midazolam-sedative","indication":"Procedural sedation and anxiolysis","status":"marketed"}]}],"pipeline":[{"name":"Elidel-Creme","genericName":"Elidel-Creme","slug":"elidel-creme","phase":"marketed","mechanism":"Elidel (pimecrolimus) is a calcineurin inhibitor that suppresses T-cell activation and inflammatory cytokine production in the skin.","indications":["Atopic dermatitis (eczema) in adults and children ≥2 years","Short-term and intermittent long-term treatment of mild to moderate atopic dermatitis"],"catalyst":""},{"name":"Piritramid (analgetic)","genericName":"Piritramid (analgetic)","slug":"piritramid-analgetic","phase":"marketed","mechanism":"Piritramid is a synthetic opioid agonist that binds to mu opioid receptors in the central nervous system to produce analgesia.","indications":["Moderate to severe acute pain","Postoperative pain"],"catalyst":""},{"name":"Therapeutic platelet transfusion","genericName":"Therapeutic platelet transfusion","slug":"therapeutic-platelet-transfusion","phase":"phase_3","mechanism":"Therapeutic platelet transfusion involves administering platelets to a patient to increase their platelet count and improve blood clotting.","indications":["Thrombocytopenia","Bleeding disorders"],"catalyst":""},{"name":"randomization between two established Chemotherapies","genericName":"randomization between two established Chemotherapies","slug":"randomization-between-two-established-chemotherapies","phase":"marketed","mechanism":"This is a randomized clinical trial comparing two established chemotherapy regimens rather than a single drug entity.","indications":[],"catalyst":""},{"name":"5-Azacytidin","genericName":"5-Azacytidin","slug":"5-azacytidin","phase":"phase_3","mechanism":"5-Azacytidine is a DNA methyltransferase inhibitor that reduces DNA methylation and promotes re-expression of silenced tumor suppressor genes.","indications":["Myelodysplastic syndromes","Acute myeloid leukemia"],"catalyst":""},{"name":"Adapalen","genericName":"Adapalen","slug":"adapalen","phase":"marketed","mechanism":"Aspartate aminotransferase, cytoplasmic, Glycine receptor subunit alpha-1, Retinoic acid receptor alpha","indications":["Acne vulgaris"],"catalyst":""},{"name":"Ciclosporine A","genericName":"Ciclosporine A","slug":"ciclosporine-a","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cytarabine Dosage","genericName":"Cytarabine Dosage","slug":"cytarabine-dosage","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone","genericName":"Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone","slug":"cytarabine-vs-cytarabine-amsacrine-mitoxantrone","phase":"marketed","mechanism":"Cytarabine is a cytidine analog that inhibits DNA synthesis, while the combination with amsacrine and mitoxantrone adds topoisomerase II inhibition and intercalating DNA damage to enhance leukemic cell killing.","indications":["Acute myeloid leukemia (AML), particularly in relapsed or refractory disease"],"catalyst":""},{"name":"Dermatop","genericName":"Dermatop","slug":"dermatop","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fludarabine (Flud)","genericName":"Fludarabine (Flud)","slug":"fludarabine-flud","phase":"marketed","mechanism":"Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to disruption of DNA synthesis and cell death in rapidly dividing cells.","indications":["Chronic lymphocytic leukemia (CLL)","Follicular lymphoma","Small lymphocytic lymphoma (SLL)"],"catalyst":""},{"name":"Gilteritinib (GILT)","genericName":"Gilteritinib (GILT)","slug":"gilteritinib-gilt","phase":"marketed","mechanism":"Gilteritinib is a tyrosine kinase inhibitor that selectively targets FLT3 (FMS-like tyrosine kinase 3) to inhibit proliferation of acute myeloid leukemia cells.","indications":["Acute myeloid leukemia (AML) with FLT3 mutation, relapsed or refractory","Acute myeloid leukemia (AML) with FLT3 mutation, newly diagnosed (in combination with chemotherapy)"],"catalyst":""},{"name":"Midazolam (sedative)","genericName":"Midazolam (sedative)","slug":"midazolam-sedative","phase":"marketed","mechanism":"Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation and anxiolysis.","indications":["Procedural sedation and anxiolysis","Induction of general anesthesia","Acute anxiety and agitation","Seizure management"],"catalyst":""},{"name":"Placebo lead in","genericName":"Placebo lead in","slug":"placebo-lead-in","phase":"phase_3","mechanism":"Placebo lead-in is a study design phase where patients receive placebo before randomization to active treatment, used to establish baseline disease progression and identify placebo responders.","indications":[],"catalyst":""},{"name":"Prophylactic platelet transfusion","genericName":"Prophylactic platelet transfusion","slug":"prophylactic-platelet-transfusion","phase":"phase_3","mechanism":"Prophylactic platelet transfusion involves administering platelets to prevent bleeding in patients with low platelet counts.","indications":["Prevention of bleeding in patients with thrombocytopenia"],"catalyst":""},{"name":"all-trans retinoid acid","genericName":"all-trans retinoid acid","slug":"all-trans-retinoid-acid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"amine fluoride/stannous fluoride","genericName":"amine fluoride/stannous fluoride","slug":"amine-fluoride-stannous-fluoride","phase":"marketed","mechanism":"Amine fluoride and stannous fluoride work together to strengthen tooth enamel and inhibit bacterial acid production to prevent dental caries.","indications":["Prevention of dental caries (cavities)","Tooth enamel strengthening"],"catalyst":""},{"name":"hydrocortisonacetat 1% cream","genericName":"hydrocortisonacetat 1% cream","slug":"hydrocortisonacetat-1-cream","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMkJYVGhhUHp2WEZXVTdweF9sRU5VOFYzTFdkQ1BFbTdZMlI4TG1BczZBWnVCMjZNTVUtMnA1TE5SMllvZEhqaVh1WDlXRF9vc0NhQTRlR3dmNVlVY3BpVU12bk5IN1dxUFJmWV9uRHB2QjRDbGN6NnpOWUxkT3QyRFAyd3ZjNkU3UDhNU1RVSHppb3k2Ry1Iek56T0g1WkZhOWhtV0laSkVDYWc?oc=5","date":"2026-01-28","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration - Genetic Engineering and Biotechnology News","headline":"Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE51TlVlSUxfenpqVERyWWF2ZGU2Tnd1OHpwdkJNSXBiLTdLbWV0Ukk1b2hVUGVXY3hxbkM4ZFNWUlZPZ2ROLXp6ZlhKYVVhVHVKd0s5ak93a1RfYjhFbnVLRFpVektBeGpa?oc=5","date":"2025-10-25","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE10MDlXUmM2VXpGYk1tY05MMlVvNnZkeFM3aWdVSlNReWk4ZmxzTDBrUkgxcEVsTExIcXBrYjd2RG96eE9HVkU4NTZJNDFKWWtIRVUxbnFSX19MLTNnZzRNaFUyQWdjNHhRQXc?oc=5","date":"2025-10-25","type":"pipeline","source":"Wiley Online Library","summary":"Journal of the European Academy of Dermatology and Venereology - Wiley Online Library","headline":"Journal of the European Academy of Dermatology and Venereology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPOFEyVGIyNXk4c09waUlpV2VTTW5uM0ZlSkMtRGVEUzA0bVlJN05TVnFPLXB0VjZ1aHBBRE9xLTgzMDJ0WVZNV2c1cmcwOFNyYzVfYi0tZlJrYTNlcjRzd0p0VEszTldYMkpmWGtDemxJRDdvWUp4WW41ZjVGYUd4bXkzWmZ3Z2JCX25OY0IxVlp2TXU1SUk0WHVub2E4d0p5SFE4enE3RGJjcG5DSUYwNUJR?oc=5","date":"2024-06-10","type":"pipeline","source":"South Carolina Daily Gazette","summary":"State-funded testing of COVID-19 treatment needs SC volunteers - South Carolina Daily Gazette","headline":"State-funded testing of COVID-19 treatment needs SC volunteers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNSk80RWV4UXJkdEJRZUM1MkFxSzdfc1doY2otaEgwOUdndHVaUFdBUC1WbGlHS0MtdENEbkVDTzZZQmg3cGY2akdmZGJaYml6a09aQlF3WTU5N0pmWS03QktCc2xvX2pqOHY1ZTZyYlhwUDg0RWF6R3ZmNnVLOGd2d0ZneHhtMngwWFBEWTFzQXpMTmFZbV90YWVxM0s2aHF6di1WZA?oc=5","date":"2023-06-01","type":"pipeline","source":"Lab Manager","summary":"Biosynthesis of Cyanobacterin Opens Up New Class of Natural Compounds - Lab Manager","headline":"Biosynthesis of Cyanobacterin Opens Up New Class of Natural Compounds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFAxc3NsYVJ3R3BKNXd3QndmTXRhV09BM3J6YThyZmpGUENZRGVPdlZCRndxTmUyMVpRNFlUOFVtUmViTDRBcFhUTnR4S3dVR1NTLW9Db3ByakxST1hxYVBnUFQteExMRmZqN3M4OQ?oc=5","date":"2023-05-17","type":"pipeline","source":"e-architect","summary":"The CUBE Dresden, Germany building - e-architect","headline":"The CUBE Dresden, Germany building - e","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNV05GRzdEX1ZfQzJjbTFyYjI0V094NEVROVZYWXVpVkdXN2ZpOWZPWmROSTZaemFFY0hwN2RrWkN5Q1lHQ0RjTl9EaE85YldELU40VlFnaUxkcUdGYjRlZUI3YlhTWGk3clNvX0x0V251QzktUHVPdnA0Y3VTalBmdTkxalFlbUZVZXZRSlhYWjgtR0E4SU1rdTlLWG1ERVd1S2NLNDlGTjlLbVhW?oc=5","date":"2022-07-04","type":"pipeline","source":"pharmaphorum","summary":"Medical Informatics and Rare Disease: a bridge between two worlds - pharmaphorum","headline":"Medical Informatics and Rare Disease: a bridge between two worlds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE1XMUVwTUVjY1h4UWE4b19TZWlLTkVjVUFoUkRJcTA0cDdnU2tGdXNlRllmU1FOZDJiZ1RwUWFSMktnWU1janU5NVBYcWQxdm5DZU1Nb0EzTzBMdlU?oc=5","date":"2022-04-25","type":"pipeline","source":"EurekAlert!","summary":"Alternative process for converting white phosphorus promises more sustainability in the chemical industry - EurekAlert!","headline":"Alternative process for converting white phosphorus promises more sustainability in the chemical industry - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE5pdnhVd0VTanJHdWxsaFdvRW5BOXhjbm5fT2tMczhFMzh0eXpnT3pVcjU1Q05iczd6NFVMYjZZMXhPWXZCWWRtVXU4Y2RjZ29FVXI2VkR5Z1g2MTA?oc=5","date":"2020-02-17","type":"pipeline","source":"EurekAlert!","summary":"An intelligent and compact particle analyzer - EurekAlert!","headline":"An intelligent and compact particle analyzer - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFA2bmVKemIwdU1TQ3J2THFRd1plTVFROHNrNk9LU2kxQkNhUkNDMi02cnRIWlJ5WmstSFhneVFSSjNWaTJ0RFM4ZWFzY09EUVdpZm9kLW9Id1F6bDA0bjdHOWFaQUUtVVdjNjVYZHhxM2lNVFdSc0hpX2NfVXU?oc=5","date":"2019-04-15","type":"trial","source":"Labiotech.eu","summary":"The Best Universities to Study Biotechnology in Europe - Labiotech.eu","headline":"The Best Universities to Study Biotechnology in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNSHB5Tmw0QjNHNVNwN0FGUU5SU1lxbjZPYVMtVERjT1BVcDhPanp4QUwtXzg0Q1VBbGZNZkw5Y3VkOVY3aTI0WWJKb01nQTg0RTJKTEdRN1VrTHpub1JTbk9yeGhtZDBwV2RNNzJpU2FvOXEydjh3WDI4b2hxbzVKbmZyVGVqRm12RUR6amZHNUVzbzVnNDROcGxzRld2NmxvRjdZazVXLTF3d0lE?oc=5","date":"2017-02-02","type":"pipeline","source":"European Medical Journal","summary":"New Developments for Parkinson’s Therapy with COMT Inhibitors - European Medical Journal","headline":"New Developments for Parkinson’s Therapy with COMT Inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPcWxsWkh3NDJBNEl4UFpmR0hBamtqZ1ctbzdkU05YUi02eEFzTTQ0ZnVkdy1oVUhFVnhfT19fYjdxTVdjclU5a0VaVm5Ucmt5SnhFWjBjWmt6eG5KTmpOdm02bGQtNFF6dTd4V3E2MjRabjdCRXNQSmRXYjc5ZkpWajc2Z25vTG01dExELW9Oc2c1MzFPWTQ4ZS1pWnBFbXJwdnNvcV91M3hZbUdiakFvRXM3X01BLWN6QUI1ZHhkRFNjRjh1dnZMU0NBOTNQNkYxRGc?oc=5","date":"2011-05-10","type":"pipeline","source":"NVIDIA Newsroom","summary":"Universities and Research Institutions Around the World Embrace Parallel Computing Using GPUs - NVIDIA Newsroom","headline":"Universities and Research Institutions Around the World Embrace Parallel Computing Using GPUs","sentiment":"neutral"}],"patents":[],"drugCount":18,"phaseCounts":{"marketed":12,"phase_3":4,"phase_1":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}